The sandwich shop has confidentially filed for an IPO, even as fast-food and sit-down chains are stuck in a discount war to ...

The PHLX Semiconductor Index, which tracks the 30 largest U.S.-listed semiconductor companies, was on pace to record its 14th straight daily gain on Monday, putting it on track for its longest winning ...

The Dow Jones Transportation Average, a price-weighted stock index of 20 major U.S. transportation companies, was on pace for a new record closing high on Monday. The index was up 480 points, or 2.1%, ...

The new Kruunuvuorensilta bridge, connecting Korkeasaari and Kruunuvuorenranta, is the longest and tallest bridge in Finland. It is also exceptional on a global scale, as bridges of this size are ...

Bitcoin edged up Monday afternoon, while U.S. stocks remained modestly lower. The largest cryptocurrency rose 0.8% to $75,612 and is up 7% over the past 30 days, according to FactSet data. However, ...

Cannabis-focused exchange-traded funds traded higher in the early afternoon on Monday — a day widely celebrated as "420" by cannabis enthusiasts for its cultural association with marijuana consumption ...

A.G.P./Alliance Global Partners is acting as the exclusive financial advisor in this warrant inducement transaction. In consideration for the immediate exercise in full of the Existing Warrants for ...

Five out of the 11 sectors in the S&P 500 were trading lower on Monday, as U.S. stocks came under pressure while investors continued to watch the prospect of peace talks between the U.S. and Iran with ...

UnitedHealth is set to report its first-quarter results before the market opens Tuesday. Here is what you need to know. PROFIT: Analysts polled by FactSet expect the company to report net income of $5 ...

Eli Lilly agreed to buy privately held cancer biotech Kelonia Therapeutics for up to $7 billion in cash, including an upfront payment of $3.25 billion. Eli Lilly on Monday said it will make subsequent ...

Arcus Biosciences is discontinuing a phase 3 lung cancer trial it was conducting with Gilead Sciences. Arcus, an oncology company, said Monday it was ending the trial due to futility, meaning it doesn ...

Biogen has agreed to pay up to $850 million to acquire TJ Bio's exclusive rights to felzartamab in the Greater China region, giving it worldwide rights to the investigational drug that is currently in ...